Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

被引：0
|
作者：
Kefang Liu
Shuguang Tan
Yan Chai
Danqing Chen
Hao Song
Catherine Wei-Hong Zhang
Yi Shi
Jun Liu
Wenjie Tan
Jianxin Lyu
Shan Gao
Jinghua Yan
Jianxun Qi
George F Gao
机构：
[1] College of Laboratory Medicine and Life Sciences,
[2] Wenzhou Medical University,undefined
[3] National Institute for Viral Disease Control and Prevention,undefined
[4] Chinese Center for Disease Control and Prevention (China CDC),undefined
[5] CAS Key Laboratory of Pathogenic Microbiology and Immunology,undefined
[6] Institute of Microbiology,undefined
[7] Chinese Academy of Sciences,undefined
[8] Research Network of Immunity and Health (RNIH),undefined
[9] Beijing Institutes of Life Science,undefined
[10] Chinese Academy of Sciences,undefined
[11] ImmuFucell Biotechnology Co.,undefined
[12] Ltd.,undefined
[13] CAS Key Laboratory of Bio-medical Diagnostics,undefined
[14] Suzhou Institute of Biomedical Engineering and Technology,undefined
[15] Chinese Academy of Sciences,undefined
[16] CAS Key Laboratory of Microbial Physiological and Metabolic Engineering,undefined
[17] Institute of Microbiology,undefined
[18] Chinese Academy of Sciences,undefined
来源：
Cell Research | 2017年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：151 / 153
页数：2
相关论文
共 50 条
  • [31] Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
    Fallon, Jonathan K.
    Vandeveer, Amanda J.
    Schlom, Jeffrey
    Greiner, John W.
    ONCOTARGET, 2017, 8 (13) : 20558 - 20571
  • [32] Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase lb JAVELIN Solid Tumor trial
    Kelly, Karen
    Patel, Manish
    Infante, Jeffrey R.
    Lannotti, Nicholas
    Nikolinakos, Petros
    Leach, Joseph
    Wang, Ding
    Chandler, Jason
    Jerusalem, Guy
    Gurtler, Jayne
    Arkenau, Henrik-Tobias
    Bajars, Marcis
    von Heydebreck, Anja
    Speit, Isabell
    Heery, Christopher R.
    Gulley, James L.
    CANCER RESEARCH, 2016, 76
  • [33] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Kathryn Lurain
    Ramya Ramaswami
    Robert Yarchoan
    Thomas S. Uldrick
    Current HIV/AIDS Reports, 2020, 17 : 547 - 556
  • [34] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Lurain, Kathryn
    Ramaswami, Ramya
    Yarchoan, Robert
    Uldrick, Thomas S.
    CURRENT HIV/AIDS REPORTS, 2020, 17 (05) : 547 - 556
  • [35] Pulmonary Sarcoidosis Associated With Anti-Pd-L1 Therapy
    Balestra, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [36] Anti-PD-L1 therapy: patient selection is important
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2016, 13 (3) : 134 - 134
  • [37] Anti-PD-L1 antibody active in metastatic bladder cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2015, 16 (01): : E11 - E11
  • [38] Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody
    Han, Xiao
    Chen, Jiawen
    Chu, Jiacheng
    Liang, Chao
    Ma, Qingle
    Fan, Qin
    Liu, Zhuang
    Wang, Chao
    JOURNAL OF CONTROLLED RELEASE, 2019, 304 : 233 - 241
  • [39] BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
    Martin Liberal, J.
    Fong, P. C.
    Moreno, V.
    Frentzas, S.
    Desai, J.
    Meniawy, T.
    Markman, B.
    Voskoboynik, M.
    Budha, N.
    Wu, J.
    Shen, W.
    Singh, M.
    Calvo, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S468 - S469
  • [40] Discordance Among Biomarkers for Anti-PD1 Therapy Response: Tumor Mutational Burden and Anti-PD-L1 Staining
    Hess, P. R.
    Velu, P. D.
    Bigdeli, A.
    Morrissette, J. J.
    Rosenbaum, J. N.
    Roth, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1039 - 1039
12345